As the vaccines roll out, so do questions and concerns. Dr. Elizabeth Connick, chief of the Division of Infectious Diseases at the UArizona College of Medicine – Tucson, called the vaccine a home run. "These are some of the most important accomplishments in medicine in the last 25 years." Overall, Dr. Connick said, it’s the same vaccine but there are a few differences. "Preliminarily, it does seem like the Moderna causes more side effects, more fatigue and particularly after the second dose. But it could be because you're getting a great immune response."

Antibody tests, groundbreaking research and community outreach are a few of the ways the University of Arizona Health Sciences met the test of a pandemic.

Dr. Amanda Sokan was recognized for her work in translational medicine that focuses on aging research, curriculum development and public health policy.

Antibody tests, groundbreaking research and community outreach are a few of the ways the University of Arizona Health Sciences met the test of a pandemic.

A UArizona Health Sciences public health student and a microbiology student in Canada won a science competition with an Instagram account to refute bad science.

An encouraging new study at the University of Arizona could lead to new immunotherapy treatments for Type-1 diabetes and could be extended to other autoimmune diseases. The study involves genetically engineered T-cells that can seek out and destroy pathogens in the pancreas. The research was led by Michael Kuhns, an associate professor of immunobiology in the UArizona College of Medicine - Tucson.

The coronavirus has upended almost all aspects of life this year, and that includes the holiday giving and volunteering that credit unions traditionally do. Kelly Reynolds, a professor and environmental microbiologist at the University of Arizona Mel and Enid Zuckerman College of Public Health, is interviewed.

Dr. Sam Keim, a professor of emergency medicine at the University of Arizona College of Medicine - Tucson, is interviewed about his experiences as a clinical trial participant in Moderna's COVID-19 vaccine

A team at the University of Arizona Health Sciences found that SARS-CoV-2 antibodies provide lasting immunity. This finding suggested that those who had survived an infection and those who received a vaccine for COVID-19 would be immune from reinfection for several months.